Thus, RNA structure might also affect intercellular communication across plants. Another key player in post-transcriptional regulations is RBP. Unlike DNA binding protein, RBP associates not only with ...

Abstract: Understanding protein secondary structure is crucial for analyzing their functions and designing drugs. Accurately predicting its eight states is both vital and challenging. Despite numerous ...

This short manuscript uses mutation counts in phylogenies of millions of SARS-CoV-2 genomes to show that mutation rates systematically differ between regions that are paired or unpaired in the ...

Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

Aims To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E ... If non-inferiority was established, superiority of the T&E regimens was evaluated. Secondary objectives included the ...

When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative ... However, the patient perspective is particularly important in Japan’s ...

Susvimo is the first FDA-approved treatment for DME that maintains vision with fewer treatments than standard injections. The refillable ocular implant delivers ranibizumab continuously, offering a ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the treatment of diabetic macular edema (DMO). According to the company, Susvimo is ...

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a refillable ocular implant. The FDA has approved Genentech’s Susvimo ...